Rinvoq could hold promise for atopic dermatitis

By Brian Buntz | July 20, 2021

The Janus kinase (JAK) inhibitor Rinvoq (upadacitinib) from AbbVie has a current indication for moderate to severe active rheumatoid arthritis for patients with an inadequate response or intolerance to the immunosuppressant methotrexate.

Rinvoq is seeking expanded approval for the drug to treat moderate to severe atopic dermatitis (AD), which is a form of eczema.

Earlier this year, FDA extended the review period for the proposed use of Rinvoq for atopic dermatitis. European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), however, issued a positive recommendation with respect to the use of the drug to treat AD in adults and adolescents.

Filed Under: Rheumatology
Tagged With: AbbVie, active rheumatoid arthritis, atopic dermatitis, Incyte, Rinvoq

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.